LONDON - Silence Therapeutics plc (NASDAQ: SLN), a biotechnology firm focusing on RNA interference (RNAi) therapies, is set to participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The company will engage in a fireside chat on February 7th, aiming to discuss its latest developments and future prospects in the field of precision-engineered medicines.
The participation in the conference is part of Silence Therapeutics' ongoing efforts to showcase its proprietary mRNAi GOLD™ platform and its pipeline of product candidates. This includes zerlasiran, which targets cardiovascular risk reduction in individuals with elevated lipoprotein(a) levels, and divesiran, aimed at rare hematological diseases such as polycythemia vera.
Silence Therapeutics has been at the forefront of utilizing RNAi to silence genes implicated in various diseases. This approach leverages the body's natural processes to inhibit gene expression and has been gaining traction in the medical community for its potential to address conditions with significant unmet needs.
The company's collaboration with industry partners such as AstraZeneca (NASDAQ:AZN), Mallinckrodt (OTC:MNKKQ) Pharmaceuticals, and Hansoh Pharma highlights its commitment to advancing its research and development initiatives.
Interested parties can access the live webcast of the fireside chat through the Investors section of the Silence Therapeutics website. A recorded version of the webcast will be made available after the conference concludes.
This engagement at the Guggenheim conference represents an opportunity for Silence Therapeutics to engage with the broader biotechnology community and investors, providing insights into its strategic direction and the impact of its RNAi-based therapies.
The information for this article is based on a press release statement from Silence Therapeutics plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.